AACR 2024 | Examining the role of tissue-agnostic ctDNA monitoring in breast cancer

Mitchell Elliott, MD, UHN Princess Margaret Cancer Centre, Toronto, Canada, delves into a prospective cohort study evaluating CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer. Baseline methylation-based tumor fraction (TF) and circulating tumor DNA (ctDNA) clearance were predictive of CDK4/6i-progression-free survival (PFS). Longitudinal sampling revealed rising methylation TF preceding clinical progression, highlighting its potential for early resistance detection. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.